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Age-related macular disease (ARMD) is a degenerative disease of the
macula, most common over the age of 50 years.1 It is the leading cause
of visual loss within western industrialised countries.2–4 The number of
blind registrations attributable to the disease increased by 30–40 %
between 1950 and 19903 and the number of cases each year is
continuing to rise4–6 as these populations have an increasing longevity.
Definition of Age-related Macular Disease
The international age-related maculopathy group has defined an
international classification system for quantifying and defining the
different subgroups of ARMD in an attempt to permit easier
comparison of research findings between groups.1
Age-related maculopathy (ARM) is a disorder of the macular area most
apparent after age 50 and is characterised by the following:
•   Areas of drusen which are external to the neuroretina and retinal
pigment epithelium (RPE). They are soft and distinct or soft and
indistinct. Hard drusen are not characteristic of ARM. Drusen 
are discrete white-yellow spots containing abnormal extracellular
lipoprotein deposits that accumulate between the RPE basal lamina
and the inner collagenous layer of Bruch’s membrane.7
•   Hyperpigmentation in the outer retina or choroid with drusen.
•   Hypopigmentation of the RPE with drusen.
This early stage of the condition may not affect vision, but can
predispose patients to visual loss (see Figure 1). 
Later stages of the condition are classified as ‘wet’ or ‘dry’ age-related
macular degeneration (AMD). These forms of the disease can occur
with or without the involvement of new blood vessel growth. If new
vessels are not involved (dry AMD), clinical presentation is a sharply
defined round or oval area of hypopigmentation where choroidal
vessels are more visible than the surrounding area, with a diameter
greater than 175 μm1 (see Figure 2). This is also known as geographic
atrophy (GA). 
The term ‘wet AMD’, also known as disciform AMD, exudative 
AMD or neovascular AMD refers to the development of 
choroidal neovascularisation (see Figure 3) and has numerous
manifestations, including:
•   choroidal neovascularisation (CNV);
•   RPE detachment(s);
•   subretinal or sub-RPE neovascular membrane(s);
•   deposition of scarring, glial tissue or fibrin-like material within the
epiretinal, intraretinal, subretinal or sub-RPE layers;
•    subretinal haemorrhages (without other retinal vascular cause); and
•   hard exudates (formed from lipid) associated with the above
manifestations (without other retinal vascular cause).
This article uses the terms ARM, AMD and ARMD as per the international
classification system described.
Physiology of Age-related Macular Disease
The RPE rests on Bruch’s membrane and separates the neural retina
from the choriocapillaris. The RPE phagocytoses the outer segment
discs of the photoreceptors and is a point of metabolite and waste
exchange, which is considered crucial to retinal function.8 The initial
signs of ARMD are variations within and below the RPE, seen 
as alterations in the pigmentation of the RPE, with or without 
the occurrence of drusen.9 Drusen are discrete white-yellow 
spots containing abnormal extracellular lipoprotein deposits that
accumulate between the RPE basal lamina and the inner collagenous
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layer of Bruch’s membrane.7 Within the ageing eye a build up of
lipofuscin granules can be seen in the RPE,10 possibly caused by 
a reduced ability of the RPE’s phagocytic-lysosomal system to
efficiently digest photoreceptor outer segment membranes,11 leading
to an accumulation of lipids from this material in Bruch’s membrane
reducing membrane permeability. This in turn may interrupt the
supply of nutrients from the choroid to the retina ultimately leading 
to photoreceptor atrophy.12 Oxidative stress causes injury and
inflammation to the RPE and choriocapillaris which may lead to an
altered extracellular matrix. This affects nutrient supply to the RPE
and retina, possibly thus further damaging the RPE and retina, leading
to the retinal atrophy seen in the later stages of ARMD.13
Aetiology of Age-related Macular Disease
Although the precise aetiology of ARMD is currently unknown, there
are several hypotheses that have been postulated.
Oxidative Stress
Ageing is associated with cumulative oxidative damage.14 The retina 
is constantly under high oxygen tension and is thus susceptible to 
this damage. Reactive oxygen intermediates (ROIs), a term used 
to describe hydrogen peroxide, singlet oxygen and free radicals, 
are synthesised as byproducts of phototransduction and cell
metabolism.15 Phagocytosis of photoreceptor outer segments by the
RPE produces ROIs, increasing oxidative stress. Outer segments of
photoreceptors contain polyunsaturated fatty acids and vitamin A.
Under high oxygen tension and light irradiation the outer segments
undergo lipid peroxidation, especially within the macular area.16 Light
irradiation induces photoreceptor damage.17 It is suggested that lipid
peroxidation may be involved in the cause of light induced retinal
degeneration.18 A healthy RPE is required for the correct functioning of
the retina19 but RPE changes occur with age as lipofuscin granules
accumulate within RPE cells. Lipofuscin is composed of vitamin A
metabolites and lipid peroxides, and is constantly exposed to visible
light (400–700 nm) and high oxygen tension (~70 mmHg),20 which
cause reactive oxygen species synthesis and possible RPE membrane
damage. Lipofuscin accumulates in the human RPE from approximately
20 years of age and continues throughout life.21 Lipofuscin is a
photosensitiser that may increase the risk of retinal photodamage and
contribute to the development of ARMD.22 There are differing thoughts
as to whether RPE melanosomes provide a protective effect to the 
RPE by scavenging reactive free radicals.23 Therefore their decline
within the RPE with increasing age24 may reduce free radical scavenging
by these cells. However, an increase in phototoxic melanin–lipofuscin
complexes (melanolipofuscin) also occur with increasing age and may
have a detrimental effect to the RPE as their accumulation more closely
reflects the onset of AMD than lipofuscin accumulation alone.25
Genetics
Although knowledge about the role of genetic variants in ARMD is
currently rudimentary, many genes have been identified as providing
either deleterious or protective effects against the disease.26,27 Several
genes have been associated with an increased risk of developing ARMD
and have been verified in further studies.28 The LOC387715 variant29 and
complement factor H gene polymorphisms (Y402H) predispose people
to an increased risk of developing ARMD.30 Protective genes have also
been identified such as the complement factor B and complement
component 2 gene, although current knowledge is limited and
continued genetic research may yield further information.31 Although
the extent of heritability and the number of genes involved in ARMD is
presently unknown32 there has been evidence to suggest increased 
risk of disease development with a positive family history of the
disease.33–36 Many studies have assessed familial predisposition to
ARMD by looking at monozygotic and dizygotic twins,34,37–41 with
monozygotic twins showing a stronger concordance than dizygotic
twins. The higher prevalence of ARMD in first-degree relatives of those
with the disease than those without the disease further strengthens the
case that genetic factors may play a part in ARMD pathogenesis.42–44
More may be learnt over time as genetic marker testing becomes
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Figure 1: Age-related Maculopathy Showing Drusen
Source: author’s own photo.
Source: author’s own photo.
Figure 2: Age-related Macular Degeneration with
Geographic Atrophy
Figure 3: Exudative Age-related Macular Degeneration
Source: Webvision, with permission.
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increasingly sophisticated, identifying greater numbers of genes
associated with ARMD. It appears likely that a combination of exposure
to environmental stimuli and genetic predisposition to ARMD are
implicated in the pathogenesis of the disease.3,45
Deterioration of Ruysch’s Complex
Ruysch’s complex consists of the RPE, Bruch’s membrane and
choriocapillaris. The hydraulic conductivity of Bruch’s membrane
reduces with increasing age.9,46,47 Bruch’s membrane collagen
solubility decreases with increasing age particularly at the posterior
pole and is thought to interfere with the function of the RPE48 whose
cell attachment rates are decreased on an aged Bruch’s membrane.49
Cross-linking of collagen fibres within Bruch’s membrane increases
with increasing age and a rise in ultraviolet absorbance and
fluorescence also occurs within the membrane.50
In ARMD, deposition of long-space collagen and basement membrane
proteins can be observed between the RPE plasma membrane and
RPE basement membrane.51 These deposits are termed basal laminar
deposits (BlamD). Basal linear deposits (BlinD) are found between 
the basement membrane of RPE cells and Bruch’s membrane (soft
drusen) mostly comprising membranous debris.52 Histopathologically,
ARMD is characterised by occurrence of both deposits.52,53 The
presence of BlamD is strongly associated with the presence of AMD,54
which compromises photoreceptor cell function,55 and BlinD are also
specific for AMD.52 Histopathological studies have correlated BlamD
with CNV56,57 and a severely compromised RPE.51
With increasing age Bruch’s membrane progressively accumulates lipid
content58,59 and fluid diffusion is slowed.46 It is thought that the debris
within Bruch’s membrane is derived from RPE metabolic activity58 and
this rise in lipid and protein quantity within Bruch’s membrane reduces
permeability, thus impeding flow of macromolecules between the RPE
and choroid.60 This may lead to slowed regeneration of photopigment
due to retinoid deficiency, ultimately causing photoreceptor loss.61
Bruch’s membrane thickens with increasing age,62 which is associated
with a decline in phagocytosis of photoreceptor outer segments by RPE
cells63 and increases the distance for oxygen transport between the
choriocapillaris and outer retina, reducing the oxygen to the outer
retina.64 In the normally functioning RPE, angiogenic growth factors such
as vascular endothelial growth factor (VEGF) and anti-angiogenic factors
like pigment-epithelium derived factor are optimally balanced within the
RPE. Oxidative stress and the accumulation of deposits within the RPE
and Bruch’s membrane may disrupt this balance65,66 upregulating VEGF,
which increases vascular permeability and angiogenesis, contributing
to the development of CNV.67–69
There is evidence that choroidal circulation attenuation may be
responsible for development of ARMD. Ninety per cent of the oxygen
requirement of the photoreceptors is provided by the choroidal
circulation70 and reduced choroidal blood flow has been associated
with ARMD.71,72 Choriocapillaris density and lumen diameter reduce with
age,73 which may decrease oxygen to the RPE and photoreceptors and
reduce clearance of waste products from Bruch’s membrane, leading
to its thickening with age.13 Retinal hypoxia increases the release of
VEGF within Ruysch’s complex leading to CNV.74 Vascular deficits are
further advanced in AMD75 with a linear relationship between reduced
choroidal blood flow and increased risk for development of CNV.76
Retinal hypoxia drives the synthesis of VEGF, which gives rise to the
angiogenesis seen in CNV.77
Factors Associated with an Increased Risk of
Age-related Macular Disease Development
There are many modifiable and non-modifiable risk factors that have
been linked with an increased risk of developing ARMD. When
reporting risk, many studies use either the odds ratio (OR) or the
relative risk (RR). The OR is the ratio of the odds of a disease occurring
in people exposed to a risk factor to the odds of it occurring in people
not exposed to a risk factor. The RR is a ratio of the probability of a
disease occurring in a risk factor exposed group versus a non-exposed
group. The hazard ratio (HR) is a ratio of the chance of events occurring
in people exposed to a risk factor compared with people not exposed
to a risk factor. Estimates of OR, RR or HR greater than 1.0 are
statistically significant and suggest a positive association or increased
risk of developing a disease. If described in the literature, statistically
significant OR, RR and HR are reported in this article. 
Modifiable Risk Factors
Smoking
Smoking is the one modifiable risk factor that has been largely
consistently associated with an increased risk of developing ARMD.78–86
The Rotterdam study found that the higher the pack-years smoked, the
higher the risk of developing neovascular AMD, with a 6.6-fold increase
in risk for developing neovascular AMD compared with non-smokers.87
The Pathologies Oculaires Liees a l’Age (POLA) study found an
increased risk of neovascular AMD and GA in people who smoked 
for more than 20 years (OR 3.0 for 20–39 pack-years and 5.2 for 40
pack-years). The risk remained elevated until 20 years after smoking
cessation.88 Smoking was not associated with risk for ARM development
in this study. Increase of ARMD development risk with increase in
smoking was also demonstrated in a study by Seddon et al.89 in a 12-year
prospective study of 31,843 women with a RR of 2.4 for developing AMD
compared with women who never smoked. This was echoed in a 12-year
prospective study of 21,157 males by Christen et al.,90 showing a RR of
2.46. The Rotterdam study results are echoed in a study on Japanese
men with an OR of 2.97 in smokers compared with non-smokers of
developing neovascular AMD.91 All of these studies show that even
previous smokers who had ceased smoking still had an elevated risk of
ARMD development compared with non-smokers, but not as elevated as
current smokers. A study undertaking pooled and separate analysis of
14,752 participants from the Beaver Dam eye study, the Rotterdam
study and the Blue Mountains eye study showed that apart from age,
smoking was the only consistent risk factor associated with any form of
ARMD (OR 3.12).92 This pooled study was taken from three different
continents (North America, Europe and Australia). Another study based
on 3,271 Australians also highlighted this consistent association for AMD
and smoking (OR 2.39).93 A review of the literature in conjunction with
New Zealand morbidity and smoking prevalence data estimated that
26.8 % of all AMD cases were attributable to current and past smoking
in New Zealand.94 In the UK, a two-fold risk of ARMD has been associated
with smoking when compared with non-smoking in 28,000 individuals
(OR 2.15).95 Cigar smoking in India has also been linked with a higher risk
for developing AMD (OR 3.29).96 A study of Latino subjects also
demonstrated an association between smoking and AMD in the Hispanic
population (OR 2.4).97 The effects of passive smoking on AMD risk have
been examined in a UK study comparing 435 people with end-stage
AMD with 280 healthy controls. The results showed an OR of 1.87 in
passive smoking exposure in non-smokers.98 This prolific evidence
across continents and differing ethnicities suggests that smoking is
highly toxic to the retina, although the pathogenic mechanisms between
smoking and retinal toxicity still remain unclear. 
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There are approximately 4,000 toxic components in cigarette smoke,
one of which is nicotine. A study assessing the effects of nicotine on 
the vascular smooth muscle cells confirmed that nicotine increases
CNV size and severity in laser-induced CNV in the mouse eye 
model.99 Nicotine attaches to nicotinic acetylcholine receptors on
photoreceptors, bipolar, horizontal and ganglion cells.100 Tar within
cigarette smoke contains hydroquinone – an oxidant that in the mouse
eye has been shown to encourage sub-RPE deposits and thickening 
of Bruch’s membrane.101 Cadmium is another toxic oxidant found in
cigarette smoke; higher urinary levels in smokers have been linked with
an increased risk of AMD.102 It accumulates at levels 2.5 times higher in
the choroid–RPE complex of smokers compared with non-smokers103
and increases reactive oxygen species, alters RPE cell morphology and
decreases cell survival.104 Studies on mice eyes have demonstrated that
chronic exposure to smoke causes changes to the RPE similar to those
observed in AMD, with RPE apoptosis, increased oxidative damage,105
DNA damage to the RPE and increased inflammatory activity.106
The effects of the combination of smoking and genetics of ARMD
have been analysed in many studies. An additive effect of smoking
for increased risk of developing ARMD has been shown when there
is a genetic disposition for the disease.107–111
Alcohol Intake
Studies assessing the association between ARMD risk and alcohol
intake have shown inconsistent findings.85,112,113 A relationship between
beer consumption and risk for CNV has been identified in the Beaver
Dam eye study (OR 1.41), although no such relationship was seen with
wine or spirit consumption.114 This was echoed in subjects from the
Latino community with beer consumption (OR 2.9) and high alcohol
intake (OR 5.8) being linked with a greater risk of developing the
disease.97 Conversely, no association between any type of alcohol 
and ARMD risk has been shown in other studies.97,115–117 Interestingly,
moderate wine consumption has been associated with a decreased
risk of developing AMD (OR 0.86)118 and in the Reykjavik eye study
alcohol consumption decreased the risk for drusen formation (OR
0.34),119 suggesting a protective effect of alcohol against ARMD. Chronic,
heavy alcohol consumption is linked with an increased accumulation of
ethyl esters and an increase in laser-induced CNV of 28 % within the 
rat choroid models.120 Ethanol is the key component of alcohol. When
photoreceptor outer segments of zebrafish are exposed to ethanol 
this leads to inhibited photoreceptor outer segment growth, leading 
to poor photoreceptor function as demonstrated by reduced a- and 
b-wave amplitudes of the electroretinogram (ERG).121 Red wine has a high
level of phenolic compounds that increase antioxidant activity, which
may reduce oxidative stress and abnormal proliferation of the RPE.122
Socioeconomic Factors
Socioeconomic factors have been inconsistently associated with 
an increased risk of developing ARMD. A Canadian study looking at
socioeconomic status and CNV found that the severity of CNV appeared
to be associated with lower socioeconomic status, although ORs or 
RRs were not provided in this study.123 However, in another Brazilian
study assessing AMD in two differing socioeconomic populations no
association between AMD and socioeconomic background was seen
(p=0.113).124 No association was demonstrated between ARMD and
socioeconomic factors in a case–control study by Hyman et al.35
or in the Framingham eye study,125 the Beaver Dam eye study126 and 
the third National Health and Nutrition Examination Survey (NHANES)
study.127 Although the underlying reasons for increased risk of 
ARMD development with lower socioeconomic status have not 
been determined, possible mechanisms include the underuse of 
eye care services, poor nutrition and exposure to adverse work 
and home environments.
Education
The Age-related eye disease study (AREDS) report number three found
that people with higher education had a lower risk for developing
drusen (OR 0.73), GA (OR 0.45) and CNV (OR 0.44).128 The Eye Disease
Case–Control Study Group (EDCCS) found a similar trend for education
and neovascular AMD risk (OR 0.7 when 12 years of education or
greater was completed compared with those who completed less
than 12 years of education), although no statistical significance was
demonstrated in their final multiple regression model.78 The first
NHANES study also demonstrated this association (OR 0.64) but
statistical significance was lost on logistic regression modelling.129 The
mechanisms associating risk for ARMD development and educational
level are not clear. People with lower educational level are more
likely to be unemployed or in lower incomes jobs, leading to poorer
socioeconomic status. Lower education may limit the ability to read
and comprehend the importance of health literature.
Nutrition
Nutrition as an associated risk factor for developing ARMD has also
been subject to conflicting findings in the literature. The first NHANES
study found high levels of dietary vitamin A provides a protective
effect against AMD (OR 0.74) with no beneficial effect shown 
with vitamin C.129 The Beaver Dam eye study found no association
between vitamins A, C and E and reduced risk of developing ARM.130
Another study of serum lycopene in the Beaver Dam eye study
showed an increased risk of ARMD with reduced lycopene levels (OR
2.2).131 However, lower levels of lutein, zeaxanthin and vitamin E were
not related to an increased risk for ARMD development in this 
study. Conversely, higher serum alpha tocopherol was found to 
be conducive to lower ARMD risk in the Baltimore longitudinal study
(OR 0.43).132 The Physicians Health study and the Blue Mountains 
eye study did not find a protective effect for vitamin C, E and
multivitamins133 and vitamin E and beta carotene134 against ARMD,
respectively. The EDCCS found a 70 % reduced risk of AMD with high
(>0.67 μmol/l) compared with low (0.25 μmol/l) levels of serum
carotenoids.135 A further study from the EDCCS reported that spinach
and collards, high in the carotenoids lutein and zeaxanthin, were
most strongly associated with a reduced risk for AMD (p<0.001).136
Collard greens are various loose-leafed vegetables of Brassica
oleracea, the same species that produces cabbage and broccoli.
They are genetically similar to kale and spring greens. Eyes with
intermediate drusen, large drusen and non-central GA of people
taking high-dose vitamins C, E, beta carotene and zinc were found to
have a lower risk (OR 0.72) of developing advanced AMD in a large
trial undertaken by the AREDS group.137 Improvements in visual
function in eyes with ARM or non-exudative AMD were reported in
several studies involving carotenoids.138–141
High levels of omega-3 fatty acid consumption (≥64.0 mg/day versus
<26.0 mg/day) have been shown to provide a protective effect against
progression to AMD (HR 0.73).142 Lowering the dietary glycaemic index
with higher omega-3 intake also showed a reduction in AMD
progression in this study (p<0.001). The benefits of a low glycaemic
diet in reducing ARM risk have been identified in other studies.142–144
The Blue Mountains eye study found a lower risk of developing ARM
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when consuming omega-3 fatty acids in the form of one serving of
fish per week (RR 0.69).145 Consumption of linoleic acid in the form 
of one to two servings of nuts per week was also associated with
reduced ARM risk in this study (RR 0.65). The AREDS studies found 
a reduction in risk of progression from drusen to GA in people with the
highest dietary intake of omega-3 fatty acid (OR 0.45)146 and reduced
risk of developing neovascular AMD (OR 0.61147 and 0.68148) and GA 
(OR 0.65).148 It is thought that omega-3 provides a protective role in the
retina by inhibiting oxidative stress and reducing inflammation in 
the retina.149
An association between higher trans-unsaturated fat intake and
increased prevalence of AMD was reported in a large study of 6,734
people (OR 1.76).150 Omega-3 fatty acids and olive oil were associated
with a reduced prevalence of ARM and AMD in this study (OR 0.85 
and 0.48, respectively). However, the third NHANES results showed no
association between dietary fat intake and ARM risk in 7,883 people151
and this was echoed in 3,654 people taking part in the Blue Mountains
eye study.152 Studies of mouse retinae have shown an increase in the
accumulation of basal laminar deposits when consuming a high fat and
cholesterol diet.153 Some studies have shown that diets higher in fats
have a propensity to be lower in essential nutrients and antioxidants.130,154
Body Mass Index 
A high body mass index (BMI) has been inconsistently linked with risk
for developing ARMD. The Blue Mountains eye study found an OR of
1.78 for risk of early ARM in people with obesity compared with those
with a normal BMI.155 The AREDS group reported that a higher BMI 
was associated with a risk for developing neovascular AMD156 and GA
(OR 1.93).157 A 2.29-fold risk of AMD and a 1.54-fold risk of pigmentary
abnormalities were demonstrated in the POLA study in people with
obesity.158 The RR was 2.35 for a BMI of 30 or more and 2.32 for a 
BMI of 25–29 for developing AMD in another study.159 Larger waist
circumference (RR 2.04) and a larger waist–hip ratio (RR 1.84) also
increased the risk of progression to AMD.159 An inverse relationship
between BMI and retinal levels of L and Z (often referred to as macular
pigment optical density) was reported.160 The authors also assessed
dietary L and Z intake and found that people with the highest BMI
consumed lower amounts of L and Z. They concluded that lower
dietary intake of L and Z, and/or competition between adipose tissue
and retina for L and Z uptake were likely to affect retinal levels of 
L and Z.160 Conversely, associations between lean men and dry AMD
have been found.161 A pooled study of 14,752 people from the Beaver
Dam eye study, the Rotterdam study and the Blue Mountains eye
study did not report any consistent association between BMI and risk
for any forms of ARMD92 and this was echoed in other studies.86,162
Cardiovascular Disease
Cardiovascular disease (CVD) has been associated with risk for
developing ARMD in several studies and discounted in others. The
Beaver Dam eye study showed no association between CVD and
neovascular AMD or GA.163 Arterial stiffness – an indicator for CVD, has
been shown to be associated with the presence of AMD.164 The Blue
Mountains eye study did show associations between CVD (RR 1.57) for
early incident ARM.165 C-Reactive protein is an inflammatory marker 
for CVD. Some studies have shown increased levels of C-reactive protein
in ARMD,166–168 suggesting an inflammatory role in the development 
of ARMD. Conversely, better cardiovascular health was associated
with an increased risk of ARMD in the Cardiovascular Health and 
Age-Related Maculopathy (CHARM) study (OR 2.54).169 The POLA study
showed a reduced risk (OR 0.72) for developing drusen and no
association between AMD and a history of cardiovascular disease.158
No association between CVD and ARMD risk was reported in the
AREDS studies,128,157 the EDCCS study78 or Smith et al.’s pooled analysis
from the Rotterdam, Blue Mountains and Beaver Dam eye studies.92
Hyman et al. found a link between ARMD and CVD (OR 1.7)35 in an
earlier study but not in a later study.170
Hyman et al. also found an association between moderate to severe
hypertension (diastolic >95 mmHg) and risk for developing neovascular
AMD (OR 4.4), especially in people receiving antihypertensive
medication.170 The same association was not found for GA and
hypertension, leading the authors to suggest that comparable disease
processes may occur in neovascular AMD and hypertension.170 Reduced
choroidal blood flow in people with hypertension with neovascular AMD
may account for this relationship.171 The Framingham eye study125 and
the first NHANES study (OR 1.5 for systolic blood pressure≥170 mmHg)129
reported links between ARMD development risk and hypertension. The
AREDS group found increased risk for developing neovascular AMD (OR
1.45) and large drusen (OR 1.19) in people with hypertension and those
taking hypertensive treatment,128 although no association with incident
neovascular AMD was seen in a further AREDS study.157 Hypertensive
disease severity has been linked with neovascular AMD, with doubled
odds in the severest of hypertension (OR 3.21).172 The Beaver Dam eye
study,173,174 the Blue Mountains eye study165, the EDCCS78 and others175,176
found no evidence to suggest that ARMD development risk and
hypertension are linked.
Cholesterol Levels and Treatment
Links between cholesterol levels, cholesterol-lowering treatments 
and risk of ARMD development have been conflicting. A possible
protective effect of statins and lipid-lowering treatments against
ARMD has been found in a number of studies (OR 0.14–0.79).177–181
Some studies have suggested statins protect the vascular endothelium
from oxidative damage182 and reduce basal linear deposit accumulation
in Bruch’s membrane by reducing cholesterol.183 Conversely, an article
assessing pooled data on the use of statins and lipid-lowering
treatments did not show a reduced risk of developing ARMD when
using statins.184 Pooled data analysis of the Beaver Dam, Rotterdam
and Blue Mountains eye studies did not report the effects of statins on
ARMD risk.92 Other studies have found no association between statin
use and reduced risk for developing ARMD.158,185–187 Furthermore, an
observational study reported an increased risk of ARMD development
in people taking statins (OR 1.19).188 In the EDCCS higher levels of
cholesterol were associated with an increased risk of neovascular
AMD (≥6.7 mm/l=OR 4.1),78 but no information about statins was
presented in this study. The AREDS study also did not provide data
about statin use or cholesterol levels.128 The benefits of statins for
reducing heart disease and lowering cholesterol were not largely
reported and routinely used until 1994189 and this is the likely reason
for the lack of data before this period. The first NHANES study found
no association between cholesterol levels and risk for ARMD
development, but again statins were not assessed here as the study
results were published in 1988.129 Higher HDL cholesterol levels were
protective for late AMD (RR per standard deviation increase 0.74), and
a high total/HDL cholesterol ratio was linked to an increased risk of
late AMD (RR per standard deviation increase 1.35) and GA (RR per
standard deviation increase 1.63) in the Blue Mountains eye study.165
Statins (HR 0.51) and aspirin (HR 0.63) were found to be associated
with reduced rates of CNV in a retrospective study of 326 patients
Risk Factors for Age-related Macular Degeneration
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as possible mechanisms for increasing AMD risk after cataract
extraction.226 Other studies, such as the AREDS group report 25, found
no risk of ARMD progression after cataract surgery.227,228 It has been
postulated that the cataract itself increases the risk of developing
ARMD. In pooled findings from three studies severe cataract was
associated with a higher prevalence of AMD, although this was not
statistically significant.229 Studies assessing the risk of ARMD
development associated with the use of newer intraocular lenses with
short-wavelength blue light filtering properties may provide more
information in the coming years. 
Cognitive Impairment
Evidence from the AREDS group showed a trend between reduced
cognitive impairment and increased risk of AMD development (p<0.01
for a mental state examination and 0.048 for a logical memory test).230
This was resonated in people with ARM in the Cardiovascular Health
Study (OR 1.38),231 a weak association in another study (OR 1.6 for
ARM)232 and in people with AMD in an Australian population (OR 2.2).233
The Rotterdam study demonstrated that tobacco and atherosclerosis
may play a role in the pathogenesis of both ARMD and Alzheimer’s
disease.234 Amyloid beta peptide is found in the neuritic plaques in
Alzheimer’s disease and also in drusen. It contributes to inflammatory
processes in both of these diseases235 and in many neurodegenerative
diseases of ageing such as Parkinson’s disease, arthritis, atherosclerosis
and myocardial infarction.236 Many people with ARMD reduce their
physical and mental activity levels, which is associated with cognitive
decline.237 Conversely, no significant relationship was established
between Alzheimer’s disease and ARMD238 in 33 people with Alzheimer’s
disease compared with 24 controls. The authors believe that a small
sample size and age differences between the groups may have
accounted for the lack of any relationship. They did not specify
between ARM or AMD for their study.
Gender
Female gender has been associated with increased risk for
development of ARMD, although no consensus seems to prevail. A
Croatian study of 6,617 patients found that ARMD incidence was
slightly increased in women compared with men (56 versus 46 %).5
This was echoed by the AREDS group, with ARM being more apparent
in women (OR 1.22)128 and in other work (no OR, RR or HR reported).216
However this was not replicated in a pooled analysis from the Beaver
Dam, Rotterdam and Blue Mountains Eye studies.92,239 Men were more
likely to undergo photodynamic therapy than women for neovascular
AMD in an Israeli study (0.21 versus 0.16  %, p=0.03)240 and were
more likely to have AMD than women in two Japanese studies
(statistical significance was not reached in one of the studies, but the
other having an OR of 2.97).241,242 The authors suggest that this may 
be due to the significantly higher proportion of Japanese men who
smoke. A recent study of the Beaver Dam offspring study also
showed that being male was associated with ARM (OR 1.65).86
Arthritis
An association between arthritis and increased likelihood of ARM was
reported in one AREDS study (OR 1.26),128 whereas another AREDS
study suggested a protective effect of anti-inflammatory medications
against AMD development (OR 0.22).157 One study found people with
rheumatoid arthritis had less prevalence of AMD and suggested 
anti-inflammatory agents, commonly used to manage the symptoms of
rheumatoid arthritis, provide a protective effect against development 
of ARMD,243 since there is some evidence that inflammation may play a
role in the development of ARMD.244 However, environmental and
genetic factors may also be relevant as rheumatoid arthritis is
commonly a disease of the young and ARMD is more apparent over
50 years of age.245
Ethnicity
Higher prevalence of ARMD has been shown in white people
compared with black people, although genetics, culture and diet may
play a role in these differences. Darker iris pigmentation may also
confer some protective effect in the black population.246 The AREDS
group found a higher risk of developing large drusen (OR 1.88) and
CNV (OR 4.22) in white people.128 A further AREDS study echoed these
results for incident CNV (OR 6.77).157 However, no such association
was found in a Brazilian study of 107 people with ARMD.124 In the
Salisbury Eye Evaluation project the risk of developing large drusen
(OR 2.10) and RPE pigmentation (OR 2.22) was higher in white people
than in black people but the risk of developing GA or CNV was no
different for white and black people.247 A south Indian study found 
a prevalence of AMD in its population similar to other developed
countries.96 A Japanese population study reported similar prevalence
of ARM to the white population of the Blue Mountains eye study. 
This similarity also held true for AMD in Japanese men, but AMD
prevalence was lower in Japanese women compared with the Blue
Mountains Eye Study population. This disparity was assumed to
occur because of a high proportion of Japanese male smokers
according to the authors.241 Another Japanese study compared the
incidence of ARMD in the Japanese population with the Beaver Dam
eye study, the Blue Mountains eye study (both with a predominantly
white population) and the Barbados eye study (a predominantly black
population).242 The authors concluded that the nine-year incidence of
ARMD was lower among the Japanese population than among white
people, but AMD was higher in the Japanese population than among
black people. The prevalence of ARM in South Koreans was also
found to be similar to other studies but the prevalence of AMD was
lower.221 Exudative AMD was found to be higher in Chinese people
(OR 4.3) compared with white people in a study assessing four
different ethnic groups, even when smoking age, gender, pupil size,
BMI, alcohol intake, diabetes and hypertension were adjusted for.248
A putative mechanism for reduced risk of ARMD in black people
compared with white people is the protective effect of the darker
pigmentation of the iris246 and higher concentrations of melanin
within the choroid of black people compared with white people.249
Melanin acts as an antioxidant, scavenging free radicals and reducing
oxidative stress.24
Iris Pigmentation
Iris pigmentation has been inconsistently associated with an increased
risk for ARMD with the EDCCS demonstrating no association between
iris colour and neovascular AMD,78,250 incident ARMD251 or GA.250
Conversely light irises were associated with increased risk for ARMD in
other studies (OR 1.22–5.0).218,252,253 Blue iris colour was linked with
increased risk of both ARM and AMD in the Blue Mountains eye study
(OR 1.69).254 However, five years later, longitudinal data did not support
this association. A study of 1,000 Danes also showed no difference
between light iris and dark iris colour for AMD.255
Hypermetropia
Hypermetropia and its associated shorter axial length have been linked
with increased ARMD development risk35,256–260 (in these studies, either
p<0.05 or OR 1.54–2.4, depending on the statistics used). An association
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with ARMD.178 Aspirin was not found to be related to an increased risk
of ARM or AMD development in the AREDS study,128 but was positively
correlated in a later AREDS study (OR 1.88).157 It was not linked in other
studies190–192 or its effects were not reported.35,78,129
Medication
Conflicting associations between the use of other medication 
and risk for developing ARMD have been reported. Those with GA
were more likely to take antacids (OR 2.13) and those with 
large drusen or extensive intermediate drusen were more likely to
take hydrochlorothiazide diuretics (OR 1.51) in one AREDS report.128
Antacid use was associated with a reduced risk of developing 
GA (OR 0.29) in another AREDS group study.157 This report also
highlighted an association between anti-inflammatory medication
and reduced incidence of GA (OR 0.22). In a further study assessing
the use of antacids and thiazide diuretics in ARMD no relationship
was found for increased risk of the disease and either medication.193
Van Leeuwen et al. found an increased risk for ARM development in
people taking antihypertensive treatment (OR 1.3) and a decreased
risk in women taking tricyclic antidepressants (OR 0.4).194
Hormones
The use of differing hormones has been associated with risk for
developing ARMD. Thyroid hormones were associated with an
increased risk of GA in the AREDS study (OR 1.99), although the use of
oestrogen and progesterone in women was not associated with any
form of ARMD in this study.128 Thyroid and antithyroid hormones were
not associated with ARMD in another study.193 There was also no
association between the use of hormone replacement therapy (HRT),
hysterectomy or oopherectomy in women and ARMD risk in the POLA
study.195 However, a protective effect of HRT was found in another study,
with a 48 % lower risk of developing CNV compared with women who
had never used HRT, although no protective effect was found for
ARM.196 A reduced risk of developing ARM was seen in another study in
women taking HRT (OR 0.6).194 A lack of oestrogen was shown to be
associated with an increase in basal laminar deposits and thickened
Bruch’s membranes in mice retinae.197 The authors postulated that
oestrogen downregulated matrix metalloproteinase-2, which is
responsible for breaking down Bruch’s membrane and RPE basement
membranes. Another study demonstrated that a lack of oestrogen
upregulates a glycoprotein called YKL-40, leading to CNV. The function
of YKL-40 in the retina is unknown.198
Type II Diabetes
Inconsistent links between type II diabetes and ARMD risk have been
described. The Blue Mountains eye study also found a relationship
between type II diabetes and development of GA after 10 years with a
RR of 3.89, but no relationship for neovascular AMD.165 Type II diabetes
was associated with an increased risk for developing ARMD compared
with type I diabetes (p<0.001) and controls (p<0.005).199 The European
Eye study (EUREYE) and AREDS group demonstrated a relationship
between type II diabetes and risk of neovascular AMD development
(OR 1.81 and 1.88, respectively) but not for GA and type II
diabetes.157,200 Conversely, a study assessing the 10-year follow-up of
133 people with newly diagnosed type II diabetes and 144 controls
found no significant difference between groups in risk for ARMD
development over the 10 years.201 No relationship between type II
diabetes and ARMD was seen in the POLA study,158 a further Blue
Mountains eye study155 or reported by others.78,92 The mechanisms 
for any association between diabetes and ARMD are unknown.
Hyperglycaemia in diabetes has been associated with reduced
choroidal circulation within the foveal area.202,203 This may reduce the
exchange of oxygen, nutrients and waste products within the outer
retina, which may increase susceptibility to ARMD.
Sunlight Exposure
There are contradictory findings in the literature about the relationship
between exposure to sunlight and risk for ARMD development. No
statistically significant associations were reported in a Brazilian study,124
an Italian study204 or studies from other global locations.78,128,205,206
Intriguingly, two studies demonstrated a protective effect of light
against ARMD (OR 0.73 in one study and annual sun exposure of
controls at 940 versus 770 hours in those with ARMD, p=0.0002).207,208
However, other studies have shown a detrimental effect of sunlight
with increased risk of ARMD development. Blue light exposure was
associated with an increased risk of developing GA in a study of 838
watermen (OR 1.36).209 The Beaver Dam eye study found a relationship
between high sunlight exposure and a higher 10-year incidence of ARM
(RR 2.20),210 with sunglasses and headwear providing protection against
drusen development (RR 0.55) and RPE depigmentation (RR 0.51). The
Blue Mountains eye study found that high (OR 2.54) and low (OR 2.18)
skin sensitivity to sunlight was associated with AMD but not ARM.211
Retinal photochemical injury occurs cumulatively over a long period 
to tolerable light levels. Sunlight damages the RPE-photoreceptor
complex, causing the formation of free radicals that peroxidise the fatty
acids within the photoreceptor outer segments, leading to RPE and
photoreceptor dysfunction and death.212 Free radicals also increase 
the production of lipofuscin in RPE cells. A2E, a major fluorophore of
lipofuscin, generates free radicals in response to light, which leads to
RPE apoptosis.213
Miscellaneous
Other, less reported modifiable risk factors inconsistently associated
with ARMD include parity greater than zero. Increased risk of
neovascular AMD has been seen with parity greater than zero in the
EDCCS study (OR 1.8)78 but this relationship is not apparent in another
study.214 Conversely, parous women were found to have a 26 % lower
risk of developing ARM196 in a more recent study. Although not clear,
hormonal mechanisms such as the effects of oestrogen mentioned
previously may play a role.
Non-modifiable Risk Factors
It is well reported that increasing age is strongly linked with a higher
risk of developing ARMD92,96,128,204,215–221 and certain genes have been
recognised for their association with disease development, but there
are other non-modifiable risk factors for developing the disease that are
inconsistent in the literature. 
Cataracts and Intraocular Lenses
Cataracts are known to protect the retina by reducing the amount 
of ultraviolet and blue light entering the eye. Thus, after cataract
extraction, the retina is subjected to increased light levels and
increased photochemical damage. The Blue Mountains eye study and
the Beaver Dam eye study found an increased risk for developing
ARMD in eyes that had undergone cataract surgery (OR 1.3–5.7 in
these studies).222–224 This was evident in other work, showing an
increased risk of AMD in eyes after cataract extraction, with
neovascular AMD developing in 19.1 % of post-cataract surgery eyes
compared with 4.3  % of non-operated fellow eyes.225 Intra-operative
photic damage and surgical inflammation have also been discussed
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between ARM risk and hypermetropia was found in the Blue Mountains
eye study (OR 2.0)261 and the Rotterdam study (OR 1.20 for advanced
hyperopia compared with emmetropia).262 In a further Blue Mountains
eye study no association was found between hypermetropia and 
the five-year incidence of ARM.263 Large drusen (OR 1.28) and CNV (OR
2.31) were associated with hypermetropia in the AREDS study.128 Other
studies have reported no effect of hypermetropia on risk for developing
ARMD.124,264 A biological mechanism for increased risk of ARMD with
hypermetropia has not yet been elucidated. One study suggests
shorter, thicker eyes with increased scleral rigidity decreases choroidal
blood flow and thus retinal nutrient and waste exchange, leading to
increased oxidative stress.262
Miscellaneous
Other, less reported non-modifiable risk factors inconsistently
associated with ARMD include hand-grip strength, optic disc
appearance and birth weight. A couple of studies have linked
decreased hand grip strength to increased risk for AMD (no OR, RR 
or HR given).35,125 Unusual optic disc appearance has been associated
with ARMD risk (no risk statistics reported)265 but repealed in other
studies.266,267 Babies with increased birth weight were found to have 
a higher possibility of developing AMD than those with lower birth
weight in one study (OR 1.5)268 and this was echoed in another study,
but only in white people for ARM (OR 1.2), although AMD risk was not
assessed in this study.269
Summary
There are many risk factors associated with ARMD development, with
varying degrees of consistency. Age, smoking and genetics appear to
be congruously linked with increased risk for developing the disease.
With the costly management of neovascular AMD and limited
treatment for dry AMD, the potential for modification of environmental
factors in reducing the risk of ARMD development is an important
research area. The oxidative stress theory for the aetiology of ARMD
provokes interest in how antioxidants may play a role in reducing the
risk of disease development and progression. n
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